22 Jan 2018 07:00
E-THERAPEUTICS PLC
("e-Therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Oxford, UK, 22 January 2018 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that on 19 January 2018 it granted a total of 2,250,000 options over its ordinary shares of 0.1 pence each to Raymond Barlow, Chief Executive Officer and a Director of the Company, and Steve Medlicott, Finance Director, as follows:
Director | Number of options granted | Scheme under which options granted | Exercise price per share |
Raymond Barlow | 1,500,000 | e-Therapeutics Performance Share Plan 2013 (One-Off Awards 2016) | 16.76 pence |
Steve Medlicott | 750,000 | e-Therapeutics Performance Share Plan 2013 (Enterprise Management Incentive Share Option Plan) | 16.76 pence |
The options are subject to the achievement of certain performance conditions and, in the event of those conditions being met, the options will vest on the following basis:
· 25% 6 months after the date of this award;
· 50% on the first anniversary of the award;
· 75% 18 months after the date of the award; and
· 100% on the second anniversary of the award.
If the conditions are not satisfied by the second anniversary (and one day) the award will lapse in its entirety.
Following this grant, Raymond Barlow holds a total of 7,000,000 options, and Steve Medlicott holds 2,750,000 options.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Raymond John Barlow |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer/Executive Director |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | e-Therapeutics plc |
b) | LEI | 21380049RHSSJXWKYT18 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence
ISIN: GB00B2823H99 |
b) | Nature of the transaction | Grant of options |
c) | Price(s) and volume(s) | 1,500,000 options over ordinary shares at an exercise price of 16.76 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 19 January 2018
|
f) | Place of the transaction | LSE, AIM |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Steven Medlicott |
2 | Reason for the notification | |
a) | Position/status | Finance Director/Executive Director |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | e-Therapeutics plc |
b) | LEI | 21380049RHSSJXWKYT18 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence
ISIN: GB00B2823H99 |
b) | Nature of the transaction | Grant of options |
c) | Price(s) and volume(s) | 750,000 options over ordinary shares at an exercise price of 16.76 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 19 January 2018
|
f) | Place of the transaction | LSE, AIM |
For further information, please contact:
Contacts:
e-Therapeutics plc Ray Barlow, Chief Financial Officer Steve Medlicott, Finance Director
| Tel: +44 (0) 1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Michael Meade / Freddie Barnfield(Corporate Finance) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
Instinctif Partners Melanie Toyne Sewell / Deborah Bell | Tel: +44 (0) 207 457 2020 Email: e-therapeutics@instinctif.com |
About e-Therapeutics plc
e-Therapeutics is an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.
Its novel methodology and Discovery Engine allow the Company to discover new and better drugs in a more efficient and effective way.
For more information about the Company, please visit www.etherapeutics.co.uk
E-therapeutics (ETX)